Avalon BioVentures — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Jnana TherapeuticsAug 2021acquired by Otsuka
Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.
Boston, US
Board seatKevin J. Kinsella· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.